We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Previous Close | 1.1800 |
Open | 1.1500 |
Bid | 1.1400 x 1100 |
Ask | 1.1500 x 1800 |
Day's Range | 1.1200 - 1.1600 |
52 Week Range | 0.9200 - 3.7900 |
Volume | |
Avg. Volume | 2,405,368 |
Market Cap | 278.529M |
Beta (5Y Monthly) | 1.16 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7700 |
Earnings Date | Nov 08, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.48 |
Subscribe to Yahoo Finance Plus to view Fair Value for LXRX
Recent insider trading activity has caught the attention of market analysts and investors alike, as Director Philippe Amouyal has made a significant purchase of shares in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX).
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today
THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place November 14-16, 2023. Jeff Wade, Lexicon’s president and chief financial officer, and Tom Garner, Lexicon’s senior vice president and chief commercial officer, will make a company presentation at 5:00 pm GMT / 12:00 pm EST on Wednesday, November 15th. A simultaneous webcast of the presentation will be ava
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript November 8, 2023 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.22. Operator: Good day and welcome to the Lexicon Pharmaceuticals’ Third Quarter 2023 Financial Results Conference Call. Today all participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, […]
Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call
Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening the opportunity for further commercial acceleration into 2024 and beyond LX9211 moving into late-stage development for the treatment of diabetic peripheral neuropathic pain Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Te
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update. Dial-in InformationU.S. Dial-in Number: (888) 317-6003International Dial-in Number: (412) 317-6061Conference ID: 2598226
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Sci
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on
Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023. Mr. Cullen brings Lexico
Symbol | Last Price | Change | % Change |
---|---|---|---|
RIGL Rigel Pharmaceuticals, Inc. | |||
ACOR Acorda Therapeutics, Inc. | |||
IMGN ImmunoGen, Inc. | |||
FOLD Amicus Therapeutics, Inc. | |||
CRIS Curis, Inc. |
Symbol | Last Price | Change | % Change |
---|---|---|---|
MCRB Seres Therapeutics, Inc. | |||
PLX Protalix BioTherapeutics, Inc. | |||
RIGL Rigel Pharmaceuticals, Inc. | |||
CHRS Coherus BioSciences, Inc. | |||
EYEN Eyenovia, Inc. |
Maintains | Citigroup: Buy to Buy | 5/31/2023 | |
Maintains | Needham: to Hold | 5/30/2023 | |
Initiated | Jefferies: to Hold | 3/7/2023 | |
Initiated | Piper Sandler: to Overweight | 8/12/2022 | |
Maintains | Citigroup: to Buy | 7/1/2022 | |
Downgrade | Wedbush: Outperform to Neutral | 1/29/2021 |
2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
281 863 3000
https://www.lexpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 135
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.